"There are particular factors that impact assay sensitivity over time," said Dr. Nathaniel Katz, Founder, President & Chief Executive Officer of Analgesic Solutions. "By identifying and monitoring for these factors using QDSS in a prospective clinical trial, we have an opportunity to intervene before these factors adversely impact the outcome of the study. Ultimately, improving assay sensitivity and data quality has the potential to pre-emptively identify poorly performing trial subjects and sites during the trial, therefore minimizing the risks to study participants, lowering the cost for sponsors and shortening the duration of clinical trials."
QDSS has now been deployed in five distinct international, multicenter clinical trials including over 7,000 subjects, 350 sites in 22 different countries. Coupled with the company's suite of proprietary training tools and consulting expertise, QDSS makes Analgesic Solutions the one stop partner for the conduct of clinical trials in the field of pain research.
Analgesic Solutions, LLC., founded in 2006, is a privately held consulting company and Clinical Research Organization. We are a hands-on team of experts who consult on, and conduct clinical trials in the process of bringing pain treatments to market. With hundreds of projects completed and ongoing collaborations with regulatory authorities, Analgesic Solutions is the premier choice for providing assistance and implementation tools for successful pain trials. Clients come to us when looking to develop and commercialize better treatments for pain. Our team, with Nathaniel Katz M.D., M.S., serving as our foremost expert, helps our clients bring their pain solutions to commercial reality.
Logo - http://photos.prnewswire.com/prnh/20160706/386655LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/analgesic-solutions-announces-presentation-of-signature-quantitative-data-surveillance-system-300337361.html
SOURCE Analgesic Solutions